Multiple sclerosis patients under treatment with interferon β1-a or ocrelizumab exhibit different T and B cell responses to SARS-CoV-2 vaccine - Scorecard - MDSpire

Multiple sclerosis patients under treatment with interferon β1-a or ocrelizumab exhibit different T and B cell responses to SARS-CoV-2 vaccine

  • By

  • Antonietta Liotti

  • Giorgia Teresa Maniscalco

  • Anne Lise Ferrara

  • Valeria Mazzone

  • Maedeh Dehbozorgi

  • Annamária Szabó

  • Martina Belardo

  • Daria Marcogiuseppe

  • Antonio De Martino

  • Maria Elena Di Battista

  • Giovanna Servillo

  • Ornella Moreggia

  • Daniele Di Giulio Cesare

  • Vincenzo Andreone

  • Gilda Varricchi

  • Veronica De Rosa

  • June 16, 2026

  • 0 min

Share

Clinical Scorecard: Differential T and B Cell Responses to SARS-CoV-2 Vaccination in Multiple Sclerosis Patients Treated with Interferon β1-a or Ocrelizumab

At a Glance

CategoryDetail
Condition
Key MechanismsImmunomodulatory effects of Disease-Modifying Therapies (DMTs) on immune response to SARS-CoV-2 vaccination.
Target Population
Care Setting

Key Highlights

  • CD20+ B-cells decreased in OCRE-treated pwMS compared to IFN-treated pwMS.
  • Comparable CD8+ and CD4+ T cell responses between both treatment groups.
  • Th17 cells increased post-vaccination only in OCRE-treated group.
  • Robust spike-specific T cell response observed in both groups.
  • Significant decrease of Treg frequency in both pwMS groups post-vaccination.

Guideline-Based Recommendations

Diagnosis

  • Evaluate immunosuppressive effects of specific DMTs during vaccination.

Management

  • Monitor immune responses in pwMS receiving DMTs during SARS-CoV-2 vaccination.

Monitoring & Follow-up

  • Assess T and B cell subsets and their responses before and after vaccination.

Risks

  • Increased susceptibility to infections and reduced vaccine efficacy in pwMS on DMTs.

Patient & Prescribing Data

Patients aged 18-65 diagnosed with MS and treated with DMTs for at least 6 months.

Clinical Best Practices

  • Conduct longitudinal studies to evaluate vaccine-induced immune responses in pwMS.

Related Resources & Content

Original Source(s)

Multiple sclerosis patients under treatment with interferon β1-a or ocrelizumab exhibit different T and B cell responses to SARS-CoV-2 vaccine

  • by Antonietta Liotti, Giorgia Teresa Maniscalco, Anne Lise Ferrara, Valeria Mazzone, Maedeh Dehbozorgi, Annamária Szabó, Martina Belardo, Daria Marcogiuseppe, Antonio De Martino, Maria Elena Di Battista, Giovanna Servillo, Ornella Moreggia, Daniele Di Giulio Cesare, Vincenzo Andreone, Gilda Varricchi, Veronica De Rosa

  • June 16, 2026

Related Content

Correction: Neurological manifestations of SARS-CoV-2 infection: protocol for a sub-analysis of the COVID-19 critical care consortium observational study

SARS-CoV-2 infection complicated by acute longitudinally extensive transverse myelitis and pulmonary embolism: a case report

The epidemiological trends of multiple sclerosis among women of child-bearing age: a global analysis from 1990 to 2021 and forecasts to 2040